Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer
Open Access
- 5 January 2010
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (3) , 577-582
Abstract
Background: Methods: Conclusions:Keywords
This publication has 31 references indexed in Scilit:
- Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patientsEuropean Journal of Surgical Oncology, 2009
- Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing ChemotherapyThe American Journal of Pathology, 2009
- Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour responseBritish Journal of Cancer, 2009
- Circulating cell death products predict clinical outcome of colorectal cancer patientsBMC Cancer, 2009
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid TumorsClinical Cancer Research, 2008
- Biomarker method validation in anticancer drug developmentBritish Journal of Pharmacology, 2008
- Compressing drug development timelines in oncology using phase '0' trialsNature Reviews Cancer, 2007
- Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cyclesBritish Journal of Cancer, 2006
- INTERMEDIATE FILAMENTS: Structure, Dynamics, Function and DiseaseAnnual Review of Biochemistry, 1994
- Intermediate Filaments: Structure, Dynamics, Function, and DiseaseAnnual Review of Biochemistry, 1994